One in Four Canadians Surveyed Had Used Cannabis Topically

A Canadian survey found 24.3% of respondents had used cannabis topically, most commonly as creams for joint stiffness, headaches, and skin conditions like eczema.

Mahmood, Farhan et al.·Journal of cutaneous medicine and surgery·2022·Preliminary EvidenceCross-Sectional
RTHC-04027Cross SectionalPreliminary Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Among survey respondents, 24.3% had used cannabis topically at least once. Creams were the most common form (26.2%). Top dermatologic uses included atopic dermatitis (25%), acne (19%), and anti-aging (16%). Top non-dermatologic uses were joint stiffness/tendonitis (30%) and headaches/migraines (27%). Users reported topical cannabis was most effective for joint stiffness, muscular soreness, headaches, eczema, and psoriasis.

Key Numbers

24.3% used topically; creams 26.2% of products; joint stiffness/tendonitis 30%; headaches/migraines 27%; atopic dermatitis 25%; acne 19%; anti-aging 16%

How They Did This

Cross-sectional anonymous electronic survey of Canadian adults assessing prevalence, purpose, and information sources for topical cannabis use following legalization.

Why This Research Matters

Topical cannabis use has expanded rapidly since legalization, but most applications lack clinical evidence. Understanding what consumers are using it for can guide research priorities.

The Bigger Picture

Consumers are using topical cannabis for a wide range of conditions based largely on dispensary advice rather than clinical evidence. This gap between use and evidence presents both opportunity and risk.

What This Study Doesn't Tell Us

Voluntary online survey with potential self-selection bias. Effectiveness ratings are self-reported perceptions, not clinical measurements.

Questions This Raises

  • ?Do topical cannabis products actually penetrate skin sufficiently to reach affected tissues?
  • ?Which of the self-reported effective uses would hold up in controlled clinical trials?

Trust & Context

Key Stat:
24.3% had used cannabis topically
Evidence Grade:
Cross-sectional voluntary survey with self-reported outcomes and potential selection bias.
Study Age:
Published in 2022
Original Title:
A Survey of Topical Cannabis Use in Canada.
Published In:
Journal of cutaneous medicine and surgery, 26(2), 156-161 (2022)
Database ID:
RTHC-04027

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

What do Canadians use topical cannabis for?

The most common uses were joint stiffness or tendonitis (30%), headaches and migraines (27%), atopic dermatitis/eczema (25%), acne (19%), and anti-aging (16%). Creams were the most popular product form.

Does topical cannabis work for skin conditions?

Users reported it was most effective for eczema, psoriasis, and muscular soreness, but these are self-reported perceptions. The study authors noted most dermatologic uses have limited clinical evidence.

Read More on RethinkTHC

Cite This Study

RTHC-04027·https://rethinkthc.com/research/RTHC-04027

APA

Mahmood, Farhan; Lim, Megan M; Kirchhof, Mark G. (2022). A Survey of Topical Cannabis Use in Canada.. Journal of cutaneous medicine and surgery, 26(2), 156-161. https://doi.org/10.1177/12034754211059025

MLA

Mahmood, Farhan, et al. "A Survey of Topical Cannabis Use in Canada.." Journal of cutaneous medicine and surgery, 2022. https://doi.org/10.1177/12034754211059025

RethinkTHC

RethinkTHC Research Database. "A Survey of Topical Cannabis Use in Canada." RTHC-04027. Retrieved from https://rethinkthc.com/research/mahmood-2022-a-survey-of-topical

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.